8th Cell & Gene Therapy World Asia 2024
Now in its 8th edition, Cell and Gene Therapy World Asia Conference at Singapore has firmly established itself as Asia's premier gathering for new partnerships, ideas, and knowledge in cell and gene therapy. We are proud to continue providing an in-person meeting platform where Asia's growing CGT industry is at the forefront, receiving increasing global attention for its rapid advancements in new therapies, R&D, and biomanufacturing.
Cryogenics Logistics World Asia 2024
The Cryogenic Logistics World Asia 2024 event aims to gather leaders and pioneers from the R&D, Manufacturing, and Logistics spaces within the Vaccines, ADCs, RNA Therapeutics, and Cell & Gene Therapy industries from the APAC region. The event helps gain insights into quality assurance, regulatory compliance, and advances in cryogenic processes, addressing real-time temperature issues and investigating game-changing improvements in cold chain transport.
3rd Biologics Contract Manufacturing Asia 2024
In 2023, the global biopharma CMO market size reached USD 17.41 billion, with projections to attain USD 39.31 billion by 2031, showcasing a dominant CAGR of 10.72%. Meanwhile, the global CDMO market size stands at USD 15.32 billion in 2024 and has a forecasted growth to USD 27.94 billion by 2029 at a CAGR of 12.78%.
While North America has traditionally dominated the CMO/CDMO market, the Asia Pacific region has emerged as the fastest-growing. Anticipated to experience a robust regional CAGR of 8.94% from 2024 to 2029, this growth is attributed to a rapidly expanding population driving demand for biolog-ics. Additional contributing factors include comparatively lower labour costs (as much as 30% lower in manufacturing alone), government policies and regulatory changes.
The 3rd Biologics Contract Manufacturing Asia 2024 is a premium event that focuses exclusively on Contract Manufacturing in Asia-Pacific. The conference addresses the growing market of contract manufacturing, the predicted trends in the market, challenges faced by CMOs/ CDMOs, as well as the solutions and opportunities moving forward. We bring the entire eco-system together — from experts in the biologics manufacturing space, to academia and regulatory — to foster partnerships, share insights and stay on the cutting edge of new developments.
Biologics Digitalization & AI World 2024
The Digitalisation and Al presence in the Global Biopharma Industry is valued at approximately USD 1784.1 Million in 2022 and is expected to exhibit a robust growth rate exceeding 5.7% 2023 to 2030. It is expected to reach $2.47 Billion by 2027.
Meanwhile, the APAC market is catching up rapidly with digitalisation as many corporates are adopting technology in their research, manufacturing and supply chain initiatives. Governments including the nations of Singapore, China, Australia, South Korea, Japan, India, Taiwan to mention a few, offer strategic incentives for biomanufacturing, promoting investment, technology adoption infrastructure development and supportive regulations to bolster the region's biopharmaceutical manufacturing capabilities.
The event this year hence features a focused track on Biologics Digitalisation & AI on the first day, 10th of September. This congregation would be a platform to meet the leaders from the Biologics World of APAC, who have pioneered in adopting AI & Digitalisation in the R&D, Manufacturing/Bioprocessing, Quality, Compliance and Supply Chain aspects to improve the efficiency of processes, productivity and to reduce cost while bringing best in quality.